Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Sareum Holdings plc
  6. Company
    SAR   GB00B02RFS12

SAREUM HOLDINGS PLC

(SAR)
  Report
Delayed Quote. Delayed London Stock Exchange - 10/25 11:35:05 am
6.45 GBX   -3.73%
04:44aSAREUM : Final Results
PU
10/21SAREUM : Notice of Results
PU
10/07SAREUM : US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Sareum Holdings plc
Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.
Sales per Business
20192020Delta
Therapeutic Drugs--0.05100%-
GBP in Million
Sales per region
20192020Delta
United Kingdom--0.05100%-
GBP in Million
Managers
Name Title Age Since
Timothy John Mitchell, Dr. Chief Executive Officer & Executive Director 60 -
John Charles Reader, Dr. Executive Director & Chief Scientific Officer 53 2012
Clive Birch Independent Non-Executive Director 67 2018
Anthony John Bunn Secretary - -
Members of the board
Name Title Age Since
Stephen B. Parker, Dr. Non-Executive Chairman 62 2016
Timothy John Mitchell, Dr. Chief Executive Officer & Executive Director 60 -
John Charles Reader, Dr. Executive Director & Chief Scientific Officer 53 2012
Michael John Owen, Dr. Non-Executive Director 69 2018
Clive Birch Independent Non-Executive Director 67 2018
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,365,701,148 3,216,776,701 95.6% 0 0.0% 95.6%
Shareholders
NameEquities%
Hargreaves Lansdown Stockbrokers Ltd. 363,001,000 10.8%
Hargreaves Lansdown Asset Management Ltd. 196,659,000 5.84%
HSBC Global Asset Management (UK) Ltd. 138,169,000 4.11%
John Charles Reader 51,625,385 1.53%
Timothy John Mitchell 50,476,073 1.50%
Jarvis Investment Management Ltd. 37,926,000 1.13%
HSBC Bank Plc (Market-Maker) 25,393,000 0.75%
IG Markets Ltd. 22,613,000 0.67%
The Share Centre Ltd. 12,859,000 0.38%
KW Investment Management Ltd. 9,870,000 0.29%
Company contact information
Sareum Holdings Plc
Unit 2A, Langford Arch
London Road
Pampisford
Cambridge, Cambridgeshire CB22 3FX

Phone : +44.1223.497700
Fax : +44.1223.497701
Web : http://www.sareum.co.uk
Brand Portfolio
In partnership withAllbrands.markets
More brands of Sareum Holdings plc
Sector Bio Therapeutic Drugs